Exclusive Summary

• Targets a massive and stable long-term market driven by global aging, addressing over 400 million BPH patients and 1.3 billion hypertension patients worldwide.
• Highly recognized clinically as a first-line therapy for BPH recommended by EAU/AUA guidelines, exceptionally beneficial for elderly men suffering from both BPH and hypertension (one drug, dual benefits).
• Patent expired globally with zero IP risks, allowing overseas distributors to seamlessly integrate it into their chronic disease portfolios and rapidly monetize through distribution models.
• Backed by China's robust supply chain and international compliant dossiers (CTD/GMP), it offers significant cost advantages, accelerating local registration and boosting competitiveness in government tenders.